SOD1 and amyotrophic lateral sclerosis: Statistical significance has not been achieved in many clinical trials, such as the case of Qalsody (used for treating ALS associated with mutations in the SOD1 gene), for which a study involving 108 participants showed no significance in slowing disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) over 28 weeks.